Upfront Therapy for the ASCT-Eligible Patient: Advances in Induction, ASCT, Consolidation, and Maintenance Therapy (https://www.myeloma.org/videos/upfront-therapy-asct-eligible-patient-advances-induction-asct-consolidation-maintenance)
click on the image above to watch the webcast
(to view the webcast in fullscreen, click on the bottom right square icon underneath the YouTube logo)
This video is the third in a five-part series that focuses on new strategies for multiple myeloma care. It was presented during the Friday Satellite Symposium preceding the 61st ASH Annual Meeting & Exposition in Orlando, FL. This video focuses on advances in induction, autologous stem cell transplant, maintenance, and consolidation for myeloma patients.
Other topics:
- Diagnosis and Risk Stratification of Plasma Cell Disorders: To Treat or Not to Treat (https://www.myeloma.org/videos/diagnosis-risk-stratification-plasma-cell-disorders-treat-or-not-treat)
- Evaluation of Upfront Therapy for the ASCT-Ineligible Patient (https://www.myeloma.org/videos/evaluation-upfront-therapy-asct-ineligible-patient)
- Upfront Therapy for the ASCT-Eligible Patient: Advances in Induction, ASCT, Consolidation, and Maintenance Therapy (https://www.myeloma.org/videos/upfront-therapy-asct-eligible-patient-advances-induction-asct-consolidation-maintenance)
- The Current Therapeutic Landscape for Relapsed or Refractory MM: Which Combinations to Use and When? (https://www.myeloma.org/videos/current-therapeutic-landscape-relapsed-or-refractory-multiple-myeloma)
- 2020 Treatment Algorithm for MM and Conclusions (https://www.myeloma.org/videos/2020-treatment-algorithm-multiple-myeloma)
Provided by the Purdue University and developed in partnership with Clinical Care Options, LLC and the International Myeloma Foundation.
Supported by educational grants from Binding Site; Celgene Corporation; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics, Inc; Oncopeptides; and Takeda Oncology.